Pharminent · Daily Brief
November 3, 2026
Regulatory & Approvals
FDA grants accelerated approval to Inovio’s Voceryq for RRP
The FDA granted accelerated approval to Inovio’s DNA-based immunotherapy Voceryq for recurrent respiratory papillomatosis (RRP). The product carries a $460,000 list price.
MedCity News →
FDA approves generic lenacapavir HIV prevention shot
The FDA approved a generic version of the HIV prevention injection lenacapavir, a step toward widening access across dozens of lower-income countries.
STAT →
uniQure’s Huntington’s gene therapy faces May FDA decision
The FDA has begun its review of uniQure’s gene therapy for Huntington’s disease, with a decision due in May, and will convene an advisory committee meeting.
Pharmaphorum →
Deals & Partnerships
Lonza to buy five US CDMO sites from Merck KGaA
Lonza has agreed to acquire five US contract development and manufacturing sites from Merck KGaA, adding 1,100 employees to Lonza’s workforce as Merck KGaA exits the CDMO business.
Pharmaceutical Technology →$MKKGY
Bavarian Nordic wins four-year UK mpox vaccine supply contract
Bavarian Nordic secured a four-year contract from the UK Government to supply its MVA-BN vaccine for the prevention of mpox and smallpox.
Pharmaceutical Technology →
EVERSANA acquires UK HEOR firm Estima
EVERSANA has acquired Estima, a UK-based AI-powered health economics and outcomes research firm, to help customers “modernise commercialisation.”
Pharmaphorum →
Business & Finance
Karyopharm files for bankruptcy, to sell itself at auction
Karyopharm will sell itself through a court-supervised auction, with the parent of cell therapy maker Gamida Cell serving as lead bidder. The company recently struck a forbearance deal to defer debt payments.
BioPharma Dive →
Pfizer raises full-year outlook and names Cecile Guegan CFO
Pfizer raised its full-year guidance alongside third-quarter results and said Cecile Guegan, who has held leadership roles at the company over the past 20 years, became CFO this month.
CNBC →$PFE
Genmab shares double after string of cancer trial wins
Genmab’s shares have doubled over three months following a series of positive cancer drug trial results, as the company moves to own more of the medicines it develops.
CNBC →
AstraZeneca sets restructuring as Alnylam and Regeneron report
AstraZeneca said it will “redeploy resources” through a new restructuring program, while Alnylam shares sold off on concerns about a top drug and Regeneron reported a record quarter.
BioPharma Dive →$AZN$REGN$ALNY
Forwarded this? Get your copy free
Sign up free →
Pharminent — Competitive Intelligence Suite · Tickers link to Yahoo Finance for reference only. Editorial framings are analysis, not investment advice. © 2026.